 | Up a level |
Number of items: 1.
Tan, Daniel Shao-Weng, Yang, James Chih-Hsin, Leighl, Natasha B., Riely, Gregory J., Sequist, Lecia V., Felip, Enriqueta, Seto, Takashi, Wolf, Juergen, Moody, Susan Elizabeth, Adams, Kenneth, Schmitz, Shu-Fang Hsu, Tan, Eugene Y. and Kim, Dong-Wan (2016). Updated results of a phase 1 study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755